Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Clinical trial
Fibrodysplasia ossificans progressiva
Heterotopic ossification
Methodology
Rare disease
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
13 11 2023
13 11 2023
Historique:
received:
22
07
2022
accepted:
24
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
The design of clinical trials in rare diseases is often complicated by a lack of real-world translational knowledge. Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by skeletal malformations and progressive heterotopic ossification (HO). Palovarotene is a selective retinoic acid receptor gamma agonist. Here, we describe the methodology of three studies in the palovarotene clinical development program in FOP and discuss insights that could inform future research, including endpoint suitability and the impact of trial design. PVO-1A-001 (NCT02322255) was a prospective, protocol-specified, longitudinal FOP natural history study (NHS). PVO-1A-201 (NCT02190747) was a randomized, double-blind, placebo-controlled phase II trial; PVO-1A-202 (NCT02279095) was its open-label extension. Trial designs, including treatment regimens and imaging assessments, were refined between PVO-1A-201 and PVO-1A-202, and within PVO-1A-202, based on emerging data as the studies progressed. Palovarotene doses were administered using a flare-up treatment regimen (higher dose for 2/4 weeks, followed by lower dose for 4/≥8 weeks; from flare-up onset), with or without accompanying chronic (daily) treatment. Flare-up and disease progression outcomes were assessed, including incidence and volume of new HO during flare-ups and/or annually, as well as other clinical, patient-reported, and exploratory outcomes. Safety was monitored throughout all studies. Overall, 114 and 58 individuals with FOP were enrolled in the NHS and phase II trials, respectively. Results of the NHS and PVO-1A-201 were published in 2022; complete results of PVO-1A-202 will be publicly available in due course. Together the studies yielded important information on endpoint suitability, including that low-dose whole-body computed tomography was the optimum imaging modality for assessing HO progression annually and that long study durations are needed to detect substantial changes in functional and patient-reported outcomes. A flexible clinical development program is necessary for underexplored rare diseases to overcome the many challenges faced. Here, the NHS provided a longitudinal evaluation of FOP progression and interventional trials were based on emerging data. The studies described informed the design and endpoints implemented in the phase III MOVE trial (NCT03312634) and provide a foundation for future clinical trial development. NCT02322255 (registered 23/12/2014); NCT02190747 (registered 15/07/2014); NCT02279095 (registered 30/10/2014).
Sections du résumé
BACKGROUND
The design of clinical trials in rare diseases is often complicated by a lack of real-world translational knowledge. Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by skeletal malformations and progressive heterotopic ossification (HO). Palovarotene is a selective retinoic acid receptor gamma agonist. Here, we describe the methodology of three studies in the palovarotene clinical development program in FOP and discuss insights that could inform future research, including endpoint suitability and the impact of trial design.
METHODS
PVO-1A-001 (NCT02322255) was a prospective, protocol-specified, longitudinal FOP natural history study (NHS). PVO-1A-201 (NCT02190747) was a randomized, double-blind, placebo-controlled phase II trial; PVO-1A-202 (NCT02279095) was its open-label extension. Trial designs, including treatment regimens and imaging assessments, were refined between PVO-1A-201 and PVO-1A-202, and within PVO-1A-202, based on emerging data as the studies progressed. Palovarotene doses were administered using a flare-up treatment regimen (higher dose for 2/4 weeks, followed by lower dose for 4/≥8 weeks; from flare-up onset), with or without accompanying chronic (daily) treatment. Flare-up and disease progression outcomes were assessed, including incidence and volume of new HO during flare-ups and/or annually, as well as other clinical, patient-reported, and exploratory outcomes. Safety was monitored throughout all studies.
RESULTS
Overall, 114 and 58 individuals with FOP were enrolled in the NHS and phase II trials, respectively. Results of the NHS and PVO-1A-201 were published in 2022; complete results of PVO-1A-202 will be publicly available in due course. Together the studies yielded important information on endpoint suitability, including that low-dose whole-body computed tomography was the optimum imaging modality for assessing HO progression annually and that long study durations are needed to detect substantial changes in functional and patient-reported outcomes.
CONCLUSIONS
A flexible clinical development program is necessary for underexplored rare diseases to overcome the many challenges faced. Here, the NHS provided a longitudinal evaluation of FOP progression and interventional trials were based on emerging data. The studies described informed the design and endpoints implemented in the phase III MOVE trial (NCT03312634) and provide a foundation for future clinical trial development.
TRIAL REGISTRATION
NCT02322255 (registered 23/12/2014); NCT02190747 (registered 15/07/2014); NCT02279095 (registered 30/10/2014).
Identifiants
pubmed: 37957586
doi: 10.1186/s12874-023-02080-7
pii: 10.1186/s12874-023-02080-7
pmc: PMC10642058
doi:
Substances chimiques
Palovarotene
28K6I5M16G
Banques de données
ClinicalTrials.gov
['NCT02190747', 'NCT02279095', 'NCT02322255']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
269Informations de copyright
© 2023. The Author(s).
Références
Calcif Tissue Int. 2021 Dec;109(6):615-625
pubmed: 34331548
J Bone Miner Res. 2023 Mar;38(3):381-394
pubmed: 36583535
Bone. 2023 Mar;168:116642
pubmed: 36526263
Bone. 2017 Aug;101:123-128
pubmed: 28465250
Ann N Y Acad Sci. 2011 Nov;1237:5-10
pubmed: 22082359
Bone. 2013 Dec;57(2):386-91
pubmed: 24051199
Orphanet J Rare Dis. 2018 Nov 6;13(1):195
pubmed: 30400970
Orphanet J Rare Dis. 2017 Jun 30;12(1):123
pubmed: 28666455
Nat Med. 2011 Apr;17(4):454-60
pubmed: 21460849
Qual Life Res. 2009 Sep;18(7):873-80
pubmed: 19543809
Am J Psychiatry. 2011 Dec;168(12):1266-77
pubmed: 22193671
Br J Clin Pharmacol. 2019 Jun;85(6):1199-1207
pubmed: 30281842
Drug Des Devel Ther. 2017 Aug 23;11:2467-2480
pubmed: 28860717
J Bone Miner Res. 2016 Sep;31(9):1666-75
pubmed: 26896819
J Bone Joint Surg Am. 2010 Mar;92(3):686-91
pubmed: 20194327
Orphanet J Rare Dis. 2021 Aug 5;16(1):350
pubmed: 34353327
J Med Genet. 1982 Feb;19(1):35-9
pubmed: 7069743
Drug Des Devel Ther. 2021 Mar 18;15:1225-1243
pubmed: 33776421
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):399-407
pubmed: 19896889
Acad Radiol. 2017 Mar;24(3):321-327
pubmed: 27989444
Bone. 2016 Sep;90:59-68
pubmed: 26891836
Genet Med. 2022 Dec;24(12):2422-2433
pubmed: 36152026
J Bone Miner Res. 2022 Oct;37(10):1891-1902
pubmed: 35854638
Eur Respir J. 2012 Aug;40(2):306-12
pubmed: 22282548
Qual Life Res. 2014 May;23(4):1221-31
pubmed: 24264804
J Bone Miner Res. 2016 Mar;31(3):650-6
pubmed: 27025942
Nat Genet. 2006 May;38(5):525-7
pubmed: 16642017
Orphanet J Rare Dis. 2019 Feb 7;14(1):31
pubmed: 30732630
Curr Opin Investig Drugs. 2009 Nov;10(11):1243-50
pubmed: 19876792
Sci Transl Med. 2015 Sep 2;7(303):303ra137
pubmed: 26333933
Orphanet J Rare Dis. 2019 May 3;14(1):98
pubmed: 31053156
J Clin Invest. 2009 Nov;119(11):3462-72
pubmed: 19855136
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:437-48
pubmed: 23858627
Bone. 2018 Apr;109:153-157
pubmed: 28963080